Alnylam Pharmaceuticals (ALNY) reports $3B 2025 revenue driven by 151% TTR franchise surge

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February ...

Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook

Jazz Pharmaceuticals is positioned for long-term value creation, with a relief rally following Q4 2025 results and the 2026 ...
MarketWatch

Vertex Pharma’s $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says

Vertex Pharmaceuticals Inc.’s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company’s rare-disease franchise by adding a potentially billion-dollar product, ...

Collegium Pharmaceutical earnings ahead: Jornay PM in focus

Wall Street rates the stock a Buy, with a mean price target of $53.67 implying roughly 19% upside from the current share price of $45.17. EPS estimates have edged down 0.3% over the past 60 days, ...
The Manila Times

Essential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension

Ventavis® is an established inhaled prostacyclin analogue for the treatment of primary pulmonary hypertensionAcquisition reinforces Essential Pharma’s mission to serve the needs of rare disease ...
The Manila Times

Zealand Pharma Announces Financial Results for the Full Year 2025

Zealand Pharma achieved notable organizational growth in 2025, with a 41% increase in the number of employees compared to 2024. Despite this rapid expansion, the company improved its high employee ...